Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
See also Monoclonal antibodies
Palivizumab is a humanized monoclonal antibody that inhibits an epitope at the A antigenic site of the F protein of respiratory syncytial virus subtypes A and B [ , ].
The most common adverse reactions to palivizumab (over 5%) are rhinitis, cough, fever, pharyngitis, bronchiolitis, and diarrhea [ ].
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here